ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Abstract Despite advancements in treating metastatic melanoma, many patients exhibit resistance to targeted therapies. Our study focuses on ATP1A1, a sodium pump subunit associated with cancer development. We aimed to assess ATP1A1 prognostic value in melanoma patients and examine the impact of its...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Laura Soumoy, Aline Genbauffe, Lena Mouchart, Alexandra Sperone, Anne Trelcat, Léa Mukeba-Harchies, Mathilde Wells, Bertrand Blankert, Ahmad Najem, Ghanem Ghanem, Sven Saussez, Fabrice Journe
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-01-01
Rangatū:	Cancer Cell International
Ngā marau:	Melanoma Resistance ATP1A1 Sodium pump Cardiotonic steroid Bufalin
Urunga tuihono:	https://doi.org/10.1186/s12935-023-03196-y
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!